{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:53:39Z","timestamp":1770821619185,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen EMEA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11523-020-00720-2","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T20:02:58Z","timestamp":1591300978000},"page":"301-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry"],"prefix":"10.1007","volume":"15","author":[{"given":"Simon","family":"Chowdhury","sequence":"first","affiliation":[]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[]},{"given":"Nicolaas","family":"Lumen","sequence":"additional","affiliation":[]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Paiss","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Gomez-Veiga","sequence":"additional","affiliation":[]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[]},{"given":"Ewa","family":"Kalinka","sequence":"additional","affiliation":[]},{"given":"Dominique","family":"Spa\u00ebth","sequence":"additional","affiliation":[]},{"given":"Susan","family":"Feyerabend","sequence":"additional","affiliation":[]},{"given":"Vsevolod","family":"Matveev","sequence":"additional","affiliation":[]},{"given":"Florence","family":"Lefresne","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Lukac","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Wapenaar","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"720_CR1","unstructured":"World Health Organization. Globocan 2018: all cancers. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf. Last update: 2018. Accessed May 17, 2019."},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387.","journal-title":"Eur J Cancer"},{"key":"720_CR3","unstructured":"American Society of Clinical Oncology. Prostate cancer: statistics. https:\/\/www.cancer.net\/cancer-types\/prostate-cancer\/statistics. Last update: Jan 2019. Accessed May 17, 2019."},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","volume":"32","author":"E Basch","year":"2014","unstructured":"Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436\u201348.","journal-title":"J Clin Oncol"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","volume":"16","author":"D Lorente","year":"2015","unstructured":"Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e279\u2013e292292.","journal-title":"Lancet Oncol"},{"key":"720_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88\u201399.","journal-title":"Eur Urol"},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73:178\u2013211.","journal-title":"Eur Urol"},{"key":"720_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"720_CR9","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"720_CR10","unstructured":"Taxotere SPC. https:\/\/www.ema.europa.eu\/documents\/product-information\/taxotere-epar-product-information_en.pdf. Last update: Accessed May 17, 2019."},{"key":"720_CR11","unstructured":"Zytiga SPC. https:\/\/www.medicines.org.uk\/emc\/files\/pil.2381.pdf. Last update: Feb 2019. Accessed May 17, 2019."},{"key":"720_CR12","unstructured":"Xtandi SPC. https:\/\/www.medicines.org.uk\/emc\/files\/pil.3203.pdf. Last update: Oct 2018. Accessed May 17, 2019."},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengelov L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189\u201397.","journal-title":"J Clin Oncol"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/bjc.2015.196","volume":"113","author":"ME Gore","year":"2015","unstructured":"Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113:12\u20139.","journal-title":"Br J Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00720-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T23:21:44Z","timestamp":1622762504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00720-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"4 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Simon Chowdhury has participated in speaker bureaus and acted as a consultant for Johnson & Johnson, Astellas, Sanofi, and Clovis and has received research grants from Clovis. Anders Bjartell has received remuneration from Janssen, Astellas, and Bayer for lectures and for participation in advisory boards. Nicolaas Lumen has participated in advisory boards for Astellas, Janssen, and Bayer, receives grants from Astellas, Janssen, Bayer, Sanofi, Ferring, and Ipsen, and receives speaker honoraria from Bayer, Astellas, Janssen, GSK, and Ipsen. Pablo Maroto has participated in advisory boards for Janssen, Astellas, and Bayer. Thomas Paiss reports no conflicts of interest. Francisco Gomez-Veiga has received remuneration from Bayer, Astellas, Janssen, and Amgen for lectures and for participation in advisory boards. Alison Birtle has participated in advisory boards and provided educational meeting support for Janssen, Astellas, Sanofi Genzyme, Bayer, and Roche. Gero Kramer reports no conflicts of interest. Ewa Kalinka has received honoraria from Janssen and Medivation\/Pfizer. Dominique Spa\u00ebth reports no conflicts of interests. Susan Feyerabend reports no conflicts of interest. Vsevolod Matveev participated in advisory boards for and received speaker honoraria from Astellas, Bayer, Janssen, and Sanofi. Florence Lefresne is an employee of Janssen Pharmaceutica N.V. and holds stock in Johnson & Johnson. Martin Lukac is an employee of Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V., Beerse, Belgium. Robert Wapenaar is an employee of Janssen-Cilag B.V. and holds stock in Johnson & Johnson. Luis Costa has participated in advisory boards for Janssen, Astellas, and Bayer, and has received speaker honoraria from Janssen and Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the ethics committees of every country that participated. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}